Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enzon Pharmaceuticals ( (ENZN) ) has issued an update.
On September 30, 2025, Enzon Pharmaceuticals, Inc. announced the Fifth Amendment to its Section 382 Rights Agreement, originally established on August 14, 2020, with Continental Stock Transfer & Trust Company as the rights agent. This amendment extends the Final Expiration Date of the rights from September 30, 2025, to December 31, 2025. The amendment reflects the company’s management belief that this extension is in the best interests of the company and its stockholders.
More about Enzon Pharmaceuticals
Average Trading Volume: 38,271
Technical Sentiment Signal: Sell
Current Market Cap: $5.93M
See more insights into ENZN stock on TipRanks’ Stock Analysis page.